Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/3/2024 | $28.00 | Buy → Neutral | UBS |
| 6/14/2022 | $47.00 | Buy | UBS |
| 5/13/2022 | $53.00 | Sector Outperform | Scotiabank |
| 4/27/2022 | $56.00 | Buy | Goldman |
| 4/14/2022 | $50.00 | Neutral → Overweight | JP Morgan |
| 4/6/2022 | $48.00 | Overweight | Morgan Stanley |
| 10/29/2021 | $50.00 | Neutral → Buy | Citigroup |
| 8/16/2021 | $51.00 → $46.00 | Equal-Weight | Morgan Stanley |
Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer FoundationThe Prize includes a charitable donation to further fund medical research NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or organizations who positively impact healthcare, was awarded to Micheal Milken. The prize includes a $250,000 charitable donation to support medical research or educational initiatives that further the recipient's work. "I am delighted to award the inaugural Royalty P
RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemiaTransaction increases Royalty Pharma's synthetic royalty funding to $925 million in 2024, highlighting the significant opportunity for this attractive funding modality NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will acquire a synthetic royalty on U.S. sales of Geron Corporation's (NASDAQ:GERN) RYTELO for $125 million in cash upfront. RYTELO was approved by the U.S. Food and Drug Administration in June 2024 for the treatment of certain adult patients with low- to intermediate-1 risk myelod
Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital Deployment of approximately $1.2 billion Raising full year 2024 guidance: Portfolio Receipts expected to be $2,750 to $2,800 million NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the third quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts. "We delivered strong growth of approximately 15% in Portfolio Receipts in the third quarter of 2024 and are delighted to raise our full year guidance" said Pablo Legorreta, Royalty Pharma's founder and Chief Executive O
SC 13G/A - Royalty Pharma plc (0001802768) (Subject)
SC 13D/A - Royalty Pharma plc (0001802768) (Subject)
SC 13G/A - Royalty Pharma plc (0001802768) (Subject)
4 - Royalty Pharma plc (0001802768) (Issuer)
4 - Royalty Pharma plc (0001802768) (Issuer)
4 - Royalty Pharma plc (0001802768) (Issuer)
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experience, responsible for designing and delivering the firm's Human Resources (HR) agenda, including onboarding, colleague engagement, professional development, compensation and benefits. Previously, Molly held a number of global HR roles of increasing responsibility at QBE Insurance Group, Perpetual Limited and National Australia Bank. Molly received her Bachelor of Arts and Master of Applied Science deg
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma's Senior Leadership Committee. Eric joins Royalty Pharma from Verisk, a global leader in data-driven analytic insights and solutions, where he was a Senior Vice President, Chief Data Officer and Chief Technology Officer, and a member of the Executive Leadership Team. During his tenure at Verisk, he led their migration to the cloud, mainframe modernization strategy and Data Governance and Data Strategy Team. Prior to Verisk, Mr. Schneider held senior IT leadership roles at Moody
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Ashwin Pai, M.D. as Executive Vice President, Investments. Ashwin will join Royalty Pharma in April 2023, and will report to Chris Hite, Executive Vice President and Vice Chairman. Ashwin joins Royalty Pharma from Morgan Stanley where he was a Managing Director and Head of West Coast Biotechnology Investment Banking. In his nearly two decade career, Ashwin has been involved in some of the most significant mergers and acquisitions transactions and partnerships in the biotechnology industry. In addition, he has advised clients on numerous capital raising events, including initial
Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $48 to $51.
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Royalty Pharma plc (NASDAQ:RPRX) Dividend Yield: 3.06% B of A Securities analyst Geoff
The offering is expected to close on June 10, 2024. Royalty Pharma intends to use the net proceeds from the Notes for general corporate purposes.
10-Q - Royalty Pharma plc (0001802768) (Filer)
8-K - Royalty Pharma plc (0001802768) (Filer)
8-K - Royalty Pharma plc (0001802768) (Filer)
Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer FoundationThe Prize includes a charitable donation to further fund medical research NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or organizations who positively impact healthcare, was awarded to Micheal Milken. The prize includes a $250,000 charitable donation to support medical research or educational initiatives that further the recipient's work. "I am delighted to award the inaugural Royalty P
RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemiaTransaction increases Royalty Pharma's synthetic royalty funding to $925 million in 2024, highlighting the significant opportunity for this attractive funding modality NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will acquire a synthetic royalty on U.S. sales of Geron Corporation's (NASDAQ:GERN) RYTELO for $125 million in cash upfront. RYTELO was approved by the U.S. Food and Drug Administration in June 2024 for the treatment of certain adult patients with low- to intermediate-1 risk myelod
Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital Deployment of approximately $1.2 billion Raising full year 2024 guidance: Portfolio Receipts expected to be $2,750 to $2,800 million NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the third quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts. "We delivered strong growth of approximately 15% in Portfolio Receipts in the third quarter of 2024 and are delighted to raise our full year guidance" said Pablo Legorreta, Royalty Pharma's founder and Chief Executive O
UBS downgraded Royalty Pharma from Buy to Neutral and set a new price target of $28.00
UBS resumed coverage of Royalty Pharma with a rating of Buy and set a new price target of $47.00
Scotiabank initiated coverage of Royalty Pharma with a rating of Sector Outperform and set a new price target of $53.00